Tarsus Pharmaceuticals, Inc.
TARS
$69.20
$0.320.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 7.32% | 6.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.32% | 6.85% | |||
| Cost of Revenue | -61.85% | 9.62% | |||
| Gross Profit | 24.17% | 6.19% | |||
| SG&A Expenses | 10.46% | 4.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.25% | 5.34% | |||
| Operating Income | -225.19% | 23.24% | |||
| Income Before Tax | -243.12% | 26.91% | |||
| Income Tax Expenses | 15.48% | 14.23% | |||
| Earnings from Continuing Operations | -166.27% | 16.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -166.27% | 16.79% | |||
| EBIT | -225.19% | 23.24% | |||
| EBITDA | -232.59% | 24.53% | |||
| EPS Basic | -163.56% | 17.12% | |||
| Normalized Basic EPS | -237.86% | -209.34% | |||
| EPS Diluted | -163.56% | 17.12% | |||
| Normalized Diluted EPS | -237.86% | -209.34% | |||
| Average Basic Shares Outstanding | 1.02% | 0.40% | |||
| Average Diluted Shares Outstanding | 1.02% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||